Predicting the impact of polypill use in a metabolic syndrome population: An effectiveness and cost-effectiveness analysis

American Journal of Cardiovascular Drugs

Volumn 13, Issue 2, 2013, Pages 121-128

  Zomer, Ella ^a   Owen, Alice ^a   Magliano, Dianna J ^a,b   Ademi, Zanfina ^a,c   Reid, Christopher M ^a   Liew, Danny ^c  

^a MONASH UNIVERSITY   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; SIMVASTATIN;

ADULT; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HIDDEN MARKOV MODEL; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PILL; PRIORITY JOURNAL;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; ASPIRIN; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DRUG COMBINATIONS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; SIMVASTATIN; TREATMENT OUTCOME;

EID: 84880676429     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.1007/s40256-013-0019-2     Document Type: Article

References (32)

1. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326:1419-25.
2. Lonn E, Bosch J, Teo KK, et al. The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. Circulation. 2010;122:2078-88.
3. Yusuf S, Pais P, Afzal R, et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet. 2009;373:1341-51.
4. Manson JE, Skerrett PJ, Greenland P, et al. The escalating pandemics of obesity and sedentary lifestyle. A call to action for clinicians. Arch Intern Med. 2004;164:249-58.
5. Grundy SM. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab. 2007;92:399-404.
6. Sun X, Faunce T. Decision-analytical modeling in health-care economic evaluations. Eur J Health Econ. 2008;9:313-23.
7. Pauker SG, Kassirer JP. Decision analysis. N Engl J Med. 1987;316:250-8.
8. O'Hagen A, McCabe C, Akehurst R, et al. Incorporation of uncertainty in health economic modeling studies. Pharmacoeconomics. 2005;23:529-36.
9. Dunstan DW, Zimmet PZ, Welborn TA, et al. The Australian Diabetes, Obesity and Lifestyle Study (AusDiab) - methods and response rates. Diabetes Res Clin Pract. 2002;57:119-29.
10. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome - a new worldwide definition. Lancet. 2005;366:1059-62.
11. Anderson KM, Odell PM, Wilson PWF, et al. Cardiovascular disease risk profiles. Am Heart J. 1990;121:293-8.
12. Zomer E, Liew D, Owen A, et al. Cardiovascular risk prediction in a population with the metabolic syndrome: Framingham vs. UKPDS algorithms. Eur J Prev Cardiol 2012. doi: 10.1177/2047487312449307 (Epub ahead of print).
13. Australian Institute of Health and Welfare 2011. National GRIM books. AIHW, 2011. http://www.aihw.gov.au/national-grim-books.
14. Steg PG, Bhatt DL, Wilson PWF, for the REACH Registry Investigators, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297(11):1197-206.
15. U.S. Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: recommendation statement. Ann Intern Med. 2009;150:396-404.
16. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making. 2002;22:340-9.
17. Greving JP, Buskens E, Koffijberg H, et al. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk. Circulation. 2008;117:2875-83.
18. Encyclopedia of Biostatistics 2nd ed. New York: Wiley; 2005.
19. Woloshin S, Schwartz LM, Moncur M, et al. Assessing values for health: numeracy matters. Med Decis Making. 2001;21:382-90.
20. Australian Government: Department of Health and Ageing. Pharmaceutical benefits scheme (PBS). http://www.pbs.gov.au. Viewed 5 Sept 2011.
21. Salkeld G, Phongsavan P, Oldenberg B, et al. The cost-effectiveness of a cardiovascular risk reduction program in general practice. Health Policy. 1997;41(2):105-19.
22. Walker A, Butler JR. Economic model system of chronic diseases in Australia; a novel approach initially focusing on diabetes and cardiovascular disease. Int J Simul Process Model. 2010;6:137-51.
23. Huynh T. Convenience care: a patient-centered mode duling. Physician Exec. 2004;30:56-8.
24. Sassi F. Calculating QALYs, comparing QALY and DALY calculations. Helath Policy Plan. 2006;21:402-8.
25. Severens JL, Milne RJ. Discounting health outcomes in economic evaluation; the ongoing debate. Value Health. 2004;7:397-401.
26. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322-38.
27. Li R, Zhang P, Barker LE, et al. Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabet Care. 2010;33:1872-94.
28. World Health Organization. Choosing interventions that are cost effective (WHO-CHOICE). Geneva: World Health Organization; 2005.
29. Vos T, Carter R, Barendregt J, et al. for the ACE-Prevention team. Assessing cost-effectiveness in prevention: ACE-prevention. Final report. University of Queensland, Brisbane and Deakin University, Melbourne 2010.
30. Sorensen HT, Mellemkjaer L, Blot WJ, et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol. 2000;95:2218-24.
31. Kelly JP, Kaufman DW, Jurgelon JM, et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet. 1996;348:1413-6.
32. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296-310.